CmAb-(IL-10) is an anti-EGFR antibody (cetuximab)-based IL-10 ICK which displayed enhanced antitumor responses on an EGFR-positive tumor mouse model associated with a reduced toxicity. Here, IL10 is linked to neoplasm.